Jumbo Sheen Fund attended the CHIPS 2026 China-Global Healthcare Investment & Partnership Summit. The inaugural CHIPS 2026 China-Global Healthcare Investment & Partnership Summit was successfully held from October 29 to 31. As a key participant, Jumbo Sheen Fund attended the event in its capacity as an investment institution while taking on a special role. Hosted by IQVIA, the conference saw Quintiles Fund as a supporting co-organiser. As the fund manager of Quintiles Fund - IQVIA's first onshore fund in China - its team took part in the conference in full depth. Leveraging this exclusive cooperation platform, Jumbo Sheen Group engaged in multi-layered exchanges with global healthcare industry partners, innovative enterprises and fellow investors. IQVIA (NYSE: IQV) is a world-leading integrated information and technology-enabled healthcare services provider, formed via the merger of two industry giants, Quintiles and IMS Health. Its business spans more than 100 countries and regions worldwide. It has long served global multinational pharmaceutical companies and maintains deep connections with numerous Chinese innovative drug and device firms, widely recognised as an industry benchmark for data, technology and professional services. Drawing on this global vision and industrial network, IQVIA co-hosted CHIPS 2026 together with CICC Capital and the China-Portugal Economic and Trade Centre, bringing global buyers, capital pools and innovative projects together at a unified transaction platform. At the conference, the Jumbo Sheen Fund team attended the keynote sessions and held in-depth discussions with industry partners and peer investors. The team exchanged views on hot topics including the commercialisation pathways of innovative drug and device pipelines, investment logic for medical hard tech, cross-border pharmaceutical collaboration opportunities, and evolving industrial policies, while actively sourcing high-quality projects with technological moats, clinical value and globalisation potential. Life sciences and healthcare represent one of the core hard-tech sectors that Jumbo Sheen Fund focuses on over the long term. Anchored in industrial value, Jumbo Sheen Group continue to deepen its footprint in biopharmaceuticals, high-end medical devices and life science technologies. Drawing on its industrial resources and investment expertise, Jumbo Sheen Group support the growth of promising innovators and help translate domestic medical innovation achievements into broader global markets. This participation marks an important step for Jumbo Sheen Fund in engaging with the medical innovation ecosystem. Going forward, Jumbo Sheen Fund will maintain close coverage of the innovative drugs and devices space, continue to identify high-growth quality targets, collaborate with ecosystem partners, and facilitate high-quality development of China's medical innovation industry. Jumbo Sheen Fund Disclaimer:The content involved in this article is for sharing and exchange purposes only, and shall not be construed as investment advice. It is provided merely for readers' reference. All copyrights of the quoted content belong to the original authors. If any infringement is found, please contact Jumbo Sheen Group for removal.

IQVIA Holdings reported third-quarter 2026 organic revenue growth of about 6%, helped by higher win rates and a steadier market. The company raised full-year 2026 guidance across all metrics. Clinical momentum came from a rebound in full-service outsourcing. Emerging biopharma demand hit a record as sector funding reached $90 billion year to date, up more than 85% year over year. Commercial Solutions benefited from a more than 40% rise in new drug launches. IQVIA has deployed 415 AI agents to improve trial site modelling, patient enrolment timelines, and real-world data insights. Margin expanded 20 basis points, net of a 70 basis point pass-through headwind. The company also removed $2.1 billion of backlog from trials inactive for over 18 months. It expects fourth-quarter interest expense of about $210 million.

IQVIA raises 2026 guidance as third-quarter revenue rises 8% to $4.43 billion. Adjusted diluted earnings per share rose 11.3% to $3.34, and the company set an Investor Day for Dec. 1. By Yash Upadhyaya Oct 27, 2026 Key takeaways. * IQVIA Holdings Inc. (IQV) reported third-quarter 2026 revenue of $4,428 million, up 8.0% from a year earlier, and net income attributable to the company of $350 million. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted diluted EPS. The results were announced on Oct. 27. IQVIA Holdings Inc. (IQV) reported third-quarter 2026 revenue of $4,428 million, up 8.0% from a year earlier, and raised its full-year 2026 guidance. Third-quarter results. Here's how the company did: * Revenue: $4,428 million vs. $4,100 million a year earlier * Diluted earnings per share: $2.10 vs. $1.93 a year earlier * Adjusted diluted earnings per share: $3.34 vs. $3.00 a year earlier * Net income attributable to IQVIA Holdings Inc.: $350 million vs. $331 million a year earlier * Adjusted EBITDA, or earnings before interest, taxes, depreciation and amortization adjusted for certain items: $1,032 million vs. $949 million a year earlier Revenue grew 8.0% on a reported basis and 8.6% at constant currency, which strips out currency movements. Adjusted EBITDA rose 8.7% from a year earlier, and Adjusted Net Income was $557 million, up from $515 million. Restructuring costs were $36 million, up from $20 million a year earlier. "IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations," said Ari Bousbib, chairman and CEO of IQVIA. Bousbib cited "strongest clinical quarterly bookings since 2022" and "over 400 AI agents deployed to date." Segments and bookings. Commercial Solutions revenue was $1,789 million, up 6.9% on a reported basis and 7.9% at constant currency. Research & Development Solutions revenue was $2,639 million, up 8.7% on a reported basis and 9.1% at constant currency. Excluding reimbursed expenses, that segment's revenue grew 6.8% on a reported basis. The company reports in two segments, Commercial Solutions and Research & Development Solutions (R&DS), after a reorganization effective Jan. 1, 2026. Prior-period segment amounts were recast to match. Net new bookings were $3.2 billion in the quarter, up 15% from a year earlier, for a book-to-bill ratio of 1.2x. Last-twelve-month net new bookings were $11.7 billion, up 14%. Backlog. The company reviewed inactive trials in its backlog estimates, resulting in an adjustment to backlog of approximately $2.1 billion. The company said the adjustment has no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog estimates. R&DS contracted backlog was $32.6 billion as of Sept. 30. The company expects about $9.4 billion of that backlog to convert to revenue in the next twelve months, growth of 10% year over year. Cash flow and balance sheet. Operating cash flow was $825 million in the quarter, and free cash flow was $667 million, from $772 million a year earlier. Free cash flow represented 120% of Adjusted Net Income for the quarter. As of Sept. 30, cash and cash equivalents were $2,249 million and debt was $16,067 million, for net debt of $13,818 million. The Net Leverage Ratio, or net debt divided by trailing twelve-month Adjusted EBITDA, was 3.45x. For the first nine months, revenue was $12,947 million, up 8.4% on a reported basis, and the company repurchased $950 million of common stock. Full-year 2026 guidance. The company raised its full-year 2026 guidance for revenue to between $17,350 million and $17,500 million. Adjusted EBITDA guidance is $4,025 million to $4,055 million, and Adjusted diluted EPS guidance is $12.90 to $13.00. The filing does not give the prior ranges, so the size of each raise is not stated. Revenue guidance includes 250 basis points of contribution from acquisitions, including deals the company expects to complete by year-end, and about 20 basis points of tailwind from foreign exchange. All guidance assumes currency rates as of Oct. 26, 2026 remain in effect for the forecast period. Investor Day. IQVIA will hold an Investor Day on Tuesday, Dec. 1, 2026. Presentations from senior executives start at 9:00 a.m. ET and conclude at about 12:30 p.m. ET. Registration is required.